Navigation Links
Overcoming resistance to anti-cancer drugs by targeting cell 'powerhouses'

Re-routing anti-cancer drugs to the "power plants" that make energy to keep cells alive is a promising but long-neglected approach to preventing emergence of the drug-resistant forms of cancer source of a serious medical problem, scientists are reporting. That's the conclusion of a new study published in the journal ACS Chemical Biology.

Shana Kelley and colleagues explain that doxorubicin and other common forms of chemotherapy work by damaging the genes inside the nucleus of cancer cells. Cancer cells divide and multiply faster than surrounding normal cells, making copies of their genes. The drugs disrupt that process. But cancer cells eventually adapt, developing structures that pump out nucleus-attacking drugs before they can work. Kelley's team explored the effects of targeting doxorubicin to the mitochondria, the energy-producing structures in cells that also contain genes.

They describe a re-targeting approach that involved mating doxorubicin with a small piece of protein that made the drug travel to mitochondria instead of the nucleus. The combo killed cancer cells, even those that had developed pumps. Such an approach could work with a whole family of anti-cancer drugs that target the nucleus, the scientists indicate.


Contact: Michael Bernstein
American Chemical Society

Page: 1

Related medicine news :

1. New finding gives clues for overcoming tamoxifen-resistant breast cancer
2. New Bold Step Renovation Stair Treads and Nosings from Martinson-Nicholls Add Slip Resistance to Stairs
3. Duke researchers describe how breast cancer cells acquire drug resistance
4. Consumer Reports Tests: Bacteria on Turkey Raised Without Antibiotics Showed Significantly Less Antibiotic Resistance than Bacteria Conventional Turkey
5. Outpatients, hospital patients face growing, but different problems with antibiotic resistance
6. Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer
7. Princess Margaret breast cancer research finds new drug target companion prognostic test for hormone therapy resistance
8. Ganetespib shows potency against ALK-positive lung cancer and overcomes crizotinib resistance
9. Other stomach microbiota modulate resistance to H. pylori-driven ulcers
10. Tiny RNA molecule may have role in polycystic ovary syndrome, insulin resistance
11. UK study: Epigenetic changes play a key role in development of chemo resistance in BCa
Post Your Comments:
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... National recruitment ... a life sciences executive with extensive sequencing and genomics experience, as Vice President of ... position, Ms. Hill will be responsible for leading the sales team in the commercialization ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: